Search research articles
Contact Us
Filters
Showing results (51-60 of 90) with videos related to
Page
of 9
Sort By:
JAMA Oncology
|
March 17, 2023
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial
Locke J Bryan, Carla Casulo, Pamela B Allen, et al.
Cancer Reports (Hoboken, N.J.)
|
July 19, 2022
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial
Carla Casulo, Armando Santoro, Guillaume Cartron, et al.
Blood Advances
|
March 22, 2021
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
Carla Casulo, Jesse G Dixon, Fang-Shu Ou, et al.
Eclinicalmedicine
|
December 16, 2024
Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial
Jonathan W Friedberg, Michael T Brady, Myla Strawderman, et al.
Leukemia & Lymphoma
|
November 3, 2025
Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort study
Nadia Toumeh, Melissa Larson, Brianna Negaard, et al.
Blood Advances
|
April 26, 2024
Defining primary refractory large B-cell lymphoma
Allison M Bock, Raphael Mwangi, Yucai Wang, et al.
Blood
|
July 13, 2014
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma
Paul M Barr, Thomas P Miller, Jonathan W Friedberg, et al.
Blood Advances
|
November 27, 2024
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium
Jonathan R Day, Melissa C Larson, Urshila Durani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Grzegorz S Nowakowski, Fangxin Hong, David W Scott, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 90) with videos related to
Sort By:
Page
of 9
JAMA Oncology
|
March 17, 2023
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial
Locke J Bryan, Carla Casulo, Pamela B Allen, et al.
Cancer Reports (Hoboken, N.J.)
|
July 19, 2022
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial
Carla Casulo, Armando Santoro, Guillaume Cartron, et al.
Blood Advances
|
March 22, 2021
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
Carla Casulo, Jesse G Dixon, Fang-Shu Ou, et al.
Eclinicalmedicine
|
December 16, 2024
Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial
Jonathan W Friedberg, Michael T Brady, Myla Strawderman, et al.
Leukemia & Lymphoma
|
November 3, 2025
Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort study
Nadia Toumeh, Melissa Larson, Brianna Negaard, et al.
Blood Advances
|
April 26, 2024
Defining primary refractory large B-cell lymphoma
Allison M Bock, Raphael Mwangi, Yucai Wang, et al.
Blood
|
July 13, 2014
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma
Paul M Barr, Thomas P Miller, Jonathan W Friedberg, et al.
Blood Advances
|
November 27, 2024
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium
Jonathan R Day, Melissa C Larson, Urshila Durani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Grzegorz S Nowakowski, Fangxin Hong, David W Scott, et al.
Page
of 9